SlideShare une entreprise Scribd logo
1  sur  10
Significance of Long-Term Exposure to Multiple APIs
Toxicity of Complex Environmental Mixtures:Major Unanswered Questions ? What is the significance of long-term exposure to multiple APIs each presentat levels below known effect levels?
The Potential forHuman Health Effects Human exposure to APIs recycled from the environment via potable water is limited. Extremely low concentrations (< 10 ng/L) Many APIs insource waters are removed by treatment Toxicological research restricted to in vitro studies and very limited epidemiological data. Concern focused primarily on vulnerable windows of exposure (e.g., fetal exposure) or to contraindicated APIs. Comparisons made with therapeutic levels are irrelevant (different mechanisms of action at ultra-low levels)
Human Exposure Function of Identities, quantities, & geographic distribution of APIs ADME Environmental transport Environmental fate Exposure routes
Key Questions Despite the years of debate and discussion, surprisingly no single, comprehensive resource exists that examines and distills what is known (and what further needs to be known) and that provides a synoptic overview of this multi-faceted topic. Key questions Where do leftover drugs accumulate in society? What causes their accumulation? What are the routes and methods used in their disposal? What portion of drug residues in the environment originate from disposal? What are the risks for humans, domestic animals, and wildlife? How can the accumulation of excess medications by consumers be minimized or eliminated? How can these unwanted drugs be best disposed? Are there potential benefits beyond reduced environmental impact by minimizing the incidence of leftover medications?
Tying Effects to Exposure Considerable evidence exists on the potential for low-dose effects from cellular and whole-organisms controlled exposures at levels lower than the nm or even pm ranges. But identifying and trying adverse consequences in non-target organisms exposed in real-world settings has met with limited success. To what extent do morphological abnormalities in aquatic organisms result from trace-level anthropogenic chemical exposures versus natural incidence? Similarly: to what extent can biological effects be maskedor concealed by ambient incident?
Tying Effects to Exposure Subtle effects, such as behavioral or immunological, can result from chronic low-level exposures from single or multiple PPCPs, each present below purported no-observed effects levels Such receptors sometimes involve receptors that differ than those in humans Mechanisms of actions (MOAs) can change as the exposure levels are reduced, and dose-response linearity can vary greatly among chemicals Furthermore, actual MOAs are frequently unknown and individual APIs can be promiscuous in their biochemical actions
Environmental Residues APIs enter the environment by three primary routes: Excretion (primarily via urine and secondarily via feces) comprises continual low-level contributions from multitudes of people Bathingreleases APIs from medications applied directly to the skin and excreted via sweat * Disposalof leftover, unwanted medications represents acute but transient and episodic contributions from fewer people Disposalis the best route for pollution prevention / source control measures ,[object Object]
Proper disposal is greatly complicated by the conflict between the need to protect public safety (e.g., from drug diversion) and the need to minimize environmental exposure* DaughtonCG and Ruhoy IS. "Environmental Footprint of Pharmaceuticals: The Significance of Factors Beyond Direct Excretion to Sewers," Environmental Toxicology & Chemistry 2009, 28(12):2495-2521; doi:10.1897/08-382.1; available: http://www3.interscience.wiley.com/cgi-bin/fulltext/123234136/PDFSTART
Sewage Treatment & Natural Attenuation  ,[object Object]

Contenu connexe

Tendances

Drug pollution or pharmaceutical pollution
Drug pollution or pharmaceutical pollutionDrug pollution or pharmaceutical pollution
Drug pollution or pharmaceutical pollutionSmawi GH
 
Setting the scene - Laurent Moulin
Setting the scene - Laurent MoulinSetting the scene - Laurent Moulin
Setting the scene - Laurent MoulinOECD Environment
 
PPCP’s and Their Impact on Our Environment
PPCP’s and Their Impact on Our EnvironmentPPCP’s and Their Impact on Our Environment
PPCP’s and Their Impact on Our EnvironmentCori LeBerth
 
Nutrient economics-report-2015
Nutrient economics-report-2015Nutrient economics-report-2015
Nutrient economics-report-2015walled ashwah
 
Session one- Mr. Nick Haigh
Session one- Mr. Nick HaighSession one- Mr. Nick Haigh
Session one- Mr. Nick HaighOECD Environment
 
Emerging contaminants and precautionary principle
Emerging contaminants and precautionary principleEmerging contaminants and precautionary principle
Emerging contaminants and precautionary principleOdgToscana
 
Session 2- Bruno Tisserand
Session 2- Bruno TisserandSession 2- Bruno Tisserand
Session 2- Bruno TisserandOECD Environment
 
Biomarkers for environmental toxicology
Biomarkers for environmental toxicologyBiomarkers for environmental toxicology
Biomarkers for environmental toxicologyAnas Ansari
 
Setting the scene - Thomas Backhaus
Setting the scene - Thomas BackhausSetting the scene - Thomas Backhaus
Setting the scene - Thomas BackhausOECD Environment
 

Tendances (18)

Career Environmental Toxicologist
Career   Environmental ToxicologistCareer   Environmental Toxicologist
Career Environmental Toxicologist
 
Ecopharmacology
EcopharmacologyEcopharmacology
Ecopharmacology
 
Drug pollution or pharmaceutical pollution
Drug pollution or pharmaceutical pollutionDrug pollution or pharmaceutical pollution
Drug pollution or pharmaceutical pollution
 
Setting the scene - Laurent Moulin
Setting the scene - Laurent MoulinSetting the scene - Laurent Moulin
Setting the scene - Laurent Moulin
 
PPCP’s and Their Impact on Our Environment
PPCP’s and Their Impact on Our EnvironmentPPCP’s and Their Impact on Our Environment
PPCP’s and Their Impact on Our Environment
 
Environmental Impact of Pharmaceuticals
Environmental Impact of PharmaceuticalsEnvironmental Impact of Pharmaceuticals
Environmental Impact of Pharmaceuticals
 
Ecopharmacology
EcopharmacologyEcopharmacology
Ecopharmacology
 
Contamination primer trabajo de la tercera unidad
Contamination primer trabajo de la tercera unidadContamination primer trabajo de la tercera unidad
Contamination primer trabajo de la tercera unidad
 
JBRM2012
JBRM2012JBRM2012
JBRM2012
 
Emerging Contaminant Threats and the Great Lakes
Emerging Contaminant Threats and the Great LakesEmerging Contaminant Threats and the Great Lakes
Emerging Contaminant Threats and the Great Lakes
 
Nutrient economics-report-2015
Nutrient economics-report-2015Nutrient economics-report-2015
Nutrient economics-report-2015
 
Session one- Mr. Nick Haigh
Session one- Mr. Nick HaighSession one- Mr. Nick Haigh
Session one- Mr. Nick Haigh
 
Emerging contaminants and precautionary principle
Emerging contaminants and precautionary principleEmerging contaminants and precautionary principle
Emerging contaminants and precautionary principle
 
Session 2- Bruno Tisserand
Session 2- Bruno TisserandSession 2- Bruno Tisserand
Session 2- Bruno Tisserand
 
Environmental Pharmacology
Environmental PharmacologyEnvironmental Pharmacology
Environmental Pharmacology
 
Biomarkers for environmental toxicology
Biomarkers for environmental toxicologyBiomarkers for environmental toxicology
Biomarkers for environmental toxicology
 
Setting the scene - Thomas Backhaus
Setting the scene - Thomas BackhausSetting the scene - Thomas Backhaus
Setting the scene - Thomas Backhaus
 
Environmental toxicology
Environmental toxicologyEnvironmental toxicology
Environmental toxicology
 

Similaire à 2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)

2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)Teleosis Institute
 
Comparison of Pharmacology and Toxicology
Comparison of Pharmacology and ToxicologyComparison of Pharmacology and Toxicology
Comparison of Pharmacology and Toxicologyshabeel pn
 
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...v2zq
 
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)Teleosis Institute
 
2.4. Environmental Impact of Disposal (Ruhoy)
2.4. Environmental Impact of Disposal (Ruhoy)2.4. Environmental Impact of Disposal (Ruhoy)
2.4. Environmental Impact of Disposal (Ruhoy)Teleosis Institute
 
Chemical Risk Assessment Traditional vs PublicHealth Perspe
Chemical Risk Assessment Traditional vs PublicHealth PerspeChemical Risk Assessment Traditional vs PublicHealth Perspe
Chemical Risk Assessment Traditional vs PublicHealth PerspeJinElias52
 
introtox-020909.pdf
introtox-020909.pdfintrotox-020909.pdf
introtox-020909.pdfAtiqaLiaqat
 
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...Bearing the Burden - Health Implications of Environmental Pollutants in Our B...
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...v2zq
 
Spokane River Health Consultation 2011
Spokane River Health Consultation 2011Spokane River Health Consultation 2011
Spokane River Health Consultation 2011Bart Mihailovich
 
CSMT 442 Cost and Estimating 2 Homework 2 `Siteworks
 CSMT 442 Cost and Estimating 2 Homework 2  `Siteworks  CSMT 442 Cost and Estimating 2 Homework 2  `Siteworks
CSMT 442 Cost and Estimating 2 Homework 2 `Siteworks MargaritoWhitt221
 
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...Environmental Protection Agency, Ireland
 
Ecotoxicology-Study aspects
Ecotoxicology-Study aspectsEcotoxicology-Study aspects
Ecotoxicology-Study aspectsijtsrd
 
toxicokinetics-1.pptx
toxicokinetics-1.pptxtoxicokinetics-1.pptx
toxicokinetics-1.pptxUnnatikhare1
 
Regulatory complexities in hp drugs
Regulatory complexities in hp drugsRegulatory complexities in hp drugs
Regulatory complexities in hp drugsBhaswat Chakraborty
 

Similaire à 2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy) (20)

2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)
 
Comparison of Pharmacology and Toxicology
Comparison of Pharmacology and ToxicologyComparison of Pharmacology and Toxicology
Comparison of Pharmacology and Toxicology
 
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...
Chemicals from the Practice of Healthcare - Challenges & Unknowns Posed by Re...
 
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
 
2.4. Environmental Impact of Disposal (Ruhoy)
2.4. Environmental Impact of Disposal (Ruhoy)2.4. Environmental Impact of Disposal (Ruhoy)
2.4. Environmental Impact of Disposal (Ruhoy)
 
839
839839
839
 
4 5 principle and scope
4 5 principle and scope4 5 principle and scope
4 5 principle and scope
 
Chemical Risk Assessment Traditional vs PublicHealth Perspe
Chemical Risk Assessment Traditional vs PublicHealth PerspeChemical Risk Assessment Traditional vs PublicHealth Perspe
Chemical Risk Assessment Traditional vs PublicHealth Perspe
 
introtox-020909.pdf
introtox-020909.pdfintrotox-020909.pdf
introtox-020909.pdf
 
Toxicity study
Toxicity studyToxicity study
Toxicity study
 
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...Bearing the Burden - Health Implications of Environmental Pollutants in Our B...
Bearing the Burden - Health Implications of Environmental Pollutants in Our B...
 
Spokane River Health Consultation 2011
Spokane River Health Consultation 2011Spokane River Health Consultation 2011
Spokane River Health Consultation 2011
 
CSMT 442 Cost and Estimating 2 Homework 2 `Siteworks
 CSMT 442 Cost and Estimating 2 Homework 2  `Siteworks  CSMT 442 Cost and Estimating 2 Homework 2  `Siteworks
CSMT 442 Cost and Estimating 2 Homework 2 `Siteworks
 
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...
Professor Michael Depledge, EPA, HSE and ESRI, Environment, Health and Wellbe...
 
1051.pdf
1051.pdf1051.pdf
1051.pdf
 
Chemical influence
Chemical influenceChemical influence
Chemical influence
 
Ecotoxicology-Study aspects
Ecotoxicology-Study aspectsEcotoxicology-Study aspects
Ecotoxicology-Study aspects
 
toxicokinetics-1.pptx
toxicokinetics-1.pptxtoxicokinetics-1.pptx
toxicokinetics-1.pptx
 
Discriptive toxicology
Discriptive toxicologyDiscriptive toxicology
Discriptive toxicology
 
Regulatory complexities in hp drugs
Regulatory complexities in hp drugsRegulatory complexities in hp drugs
Regulatory complexities in hp drugs
 

Plus de Teleosis Institute

3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)Teleosis Institute
 
3.4. What is Accumulating & How Do We Know? (Kreisberg)
3.4. What is Accumulating & How Do We Know? (Kreisberg)3.4. What is Accumulating & How Do We Know? (Kreisberg)
3.4. What is Accumulating & How Do We Know? (Kreisberg)Teleosis Institute
 
3.3. The Reality of Non-Compliance
3.3. The Reality of Non-Compliance3.3. The Reality of Non-Compliance
3.3. The Reality of Non-ComplianceTeleosis Institute
 
3.2. Life Cycle Dynamics (Kreisberg)
3.2. Life Cycle Dynamics (Kreisberg)3.2. Life Cycle Dynamics (Kreisberg)
3.2. Life Cycle Dynamics (Kreisberg)Teleosis Institute
 
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)Teleosis Institute
 
5.5. State Regulations and Guidance (Batz)
5.5. State Regulations and Guidance (Batz)5.5. State Regulations and Guidance (Batz)
5.5. State Regulations and Guidance (Batz)Teleosis Institute
 
5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)Teleosis Institute
 
5.3. Methods of Disposal (Batz)
5.3. Methods of Disposal (Batz)5.3. Methods of Disposal (Batz)
5.3. Methods of Disposal (Batz)Teleosis Institute
 
5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)Teleosis Institute
 
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...Teleosis Institute
 

Plus de Teleosis Institute (13)

3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)
 
3.4. What is Accumulating & How Do We Know? (Kreisberg)
3.4. What is Accumulating & How Do We Know? (Kreisberg)3.4. What is Accumulating & How Do We Know? (Kreisberg)
3.4. What is Accumulating & How Do We Know? (Kreisberg)
 
3.3. The Reality of Non-Compliance
3.3. The Reality of Non-Compliance3.3. The Reality of Non-Compliance
3.3. The Reality of Non-Compliance
 
3.2. Life Cycle Dynamics (Kreisberg)
3.2. Life Cycle Dynamics (Kreisberg)3.2. Life Cycle Dynamics (Kreisberg)
3.2. Life Cycle Dynamics (Kreisberg)
 
3.1. Introduction (Kreisberg)
3.1. Introduction (Kreisberg)3.1. Introduction (Kreisberg)
3.1. Introduction (Kreisberg)
 
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
3.6. Reducing Pharmaceutical Waste in Clinical Care (Kreisberg)
 
5.5. State Regulations and Guidance (Batz)
5.5. State Regulations and Guidance (Batz)5.5. State Regulations and Guidance (Batz)
5.5. State Regulations and Guidance (Batz)
 
5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)
 
5.3. Methods of Disposal (Batz)
5.3. Methods of Disposal (Batz)5.3. Methods of Disposal (Batz)
5.3. Methods of Disposal (Batz)
 
5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)
 
5.6. Conclusion (Batz)
5.6. Conclusion (Batz)5.6. Conclusion (Batz)
5.6. Conclusion (Batz)
 
5.1. Introduction (Batz)
5.1. Introduction (Batz)5.1. Introduction (Batz)
5.1. Introduction (Batz)
 
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introductio...
 

2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)

  • 1. Significance of Long-Term Exposure to Multiple APIs
  • 2. Toxicity of Complex Environmental Mixtures:Major Unanswered Questions ? What is the significance of long-term exposure to multiple APIs each presentat levels below known effect levels?
  • 3. The Potential forHuman Health Effects Human exposure to APIs recycled from the environment via potable water is limited. Extremely low concentrations (< 10 ng/L) Many APIs insource waters are removed by treatment Toxicological research restricted to in vitro studies and very limited epidemiological data. Concern focused primarily on vulnerable windows of exposure (e.g., fetal exposure) or to contraindicated APIs. Comparisons made with therapeutic levels are irrelevant (different mechanisms of action at ultra-low levels)
  • 4. Human Exposure Function of Identities, quantities, & geographic distribution of APIs ADME Environmental transport Environmental fate Exposure routes
  • 5. Key Questions Despite the years of debate and discussion, surprisingly no single, comprehensive resource exists that examines and distills what is known (and what further needs to be known) and that provides a synoptic overview of this multi-faceted topic. Key questions Where do leftover drugs accumulate in society? What causes their accumulation? What are the routes and methods used in their disposal? What portion of drug residues in the environment originate from disposal? What are the risks for humans, domestic animals, and wildlife? How can the accumulation of excess medications by consumers be minimized or eliminated? How can these unwanted drugs be best disposed? Are there potential benefits beyond reduced environmental impact by minimizing the incidence of leftover medications?
  • 6. Tying Effects to Exposure Considerable evidence exists on the potential for low-dose effects from cellular and whole-organisms controlled exposures at levels lower than the nm or even pm ranges. But identifying and trying adverse consequences in non-target organisms exposed in real-world settings has met with limited success. To what extent do morphological abnormalities in aquatic organisms result from trace-level anthropogenic chemical exposures versus natural incidence? Similarly: to what extent can biological effects be maskedor concealed by ambient incident?
  • 7. Tying Effects to Exposure Subtle effects, such as behavioral or immunological, can result from chronic low-level exposures from single or multiple PPCPs, each present below purported no-observed effects levels Such receptors sometimes involve receptors that differ than those in humans Mechanisms of actions (MOAs) can change as the exposure levels are reduced, and dose-response linearity can vary greatly among chemicals Furthermore, actual MOAs are frequently unknown and individual APIs can be promiscuous in their biochemical actions
  • 8.
  • 9. Proper disposal is greatly complicated by the conflict between the need to protect public safety (e.g., from drug diversion) and the need to minimize environmental exposure* DaughtonCG and Ruhoy IS. "Environmental Footprint of Pharmaceuticals: The Significance of Factors Beyond Direct Excretion to Sewers," Environmental Toxicology & Chemistry 2009, 28(12):2495-2521; doi:10.1897/08-382.1; available: http://www3.interscience.wiley.com/cgi-bin/fulltext/123234136/PDFSTART
  • 10.
  • 11. Concentrations in treated sewage often range from 1-100 ng/L.
  • 12. “Removal” does not necessarily equate with “destruction” or with elimination of toxicity.
  • 13. Parent (unchanged) APIs can partition to solid sludge (biosolids).
  • 15.